Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of
chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic …

Background Gastric cancer is the fifth most common cancer worldwide. In" Western"
countries, most people are either diagnosed at an advanced stage, or develop a relapse …

Almost one million (951 600) new cases of gastric cancer were diagnosed globally in 2012,
resulting in∼ 723 100 deaths [1]. Of these∼ 140 000 cases and∼ 107 000 deaths occurred …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer (GC) was …

5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as
for its synergism with other anticancer drugs, has been used to treat various types of …

In dieser Leitlinie sind eingetragene Warenzeichen (geschützte Warennamen) nicht
besonders kenntlich gemacht. Es kann also aus dem Fehlen eines entsprechenden …

Background: A globally accepted standard first-line chemotherapy regimen in advanced
esophagogastric cancer (AEGC) is not clearly established. We conducted a systematic …

Summary Background Capecitabine plus oxaliplatin (CapeOX) is one of the reference
doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer. We …

The fluoropyrimidines, namely 5-fluorouracil (5-FU) and its oral prodrug, capecitabine, are
the third most commonly used chemotherapeutic agents for the treatment of solid tumors of …

Background This study was designed to determine the surgical outcomes of gastric cancer
in elderly patients. This information can help establish appropriate treatment for these …